Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 3500
- Registration Number
- NCT00266136
- Locations
- 🇩🇪
University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology, Muenster, Germany
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2005-11-28
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00219765
- Locations
- 🇫🇷
University Hospital, Poitiers, France
Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2005-11-18
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 200
- Registration Number
- NCT00209833
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT00199017
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: DexamethasoneDrug: VincristineDrug: DaunorubicinDrug: AsparaginaseDrug: MethotrexateDrug: CytarabineDrug: MercaptopurineDrug: G-CSFDrug: VindesineDrug: EtoposideDrug: PrednisoloneDrug: AdriamycinDrug: ThioguanineDrug: TeniposideProcedure: CNS irradiationProcedure: Mediastinal IrradiationProcedure: Stem cell transplantation (SCT)Drug: IdarubicinDrug: FludarabineDrug: Cladribine
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 1883
- Registration Number
- NCT00198991
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2010-08-23
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00199004
- Locations
- 🇩🇪
University Hospital of Frankfurt, Medical Dept. II, Frankfurt, Germany
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 225
- Registration Number
- NCT00199056
- Locations
- 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 80
- Registration Number
- NCT00180128
- Locations
- 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT00187122
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.